migalastat


( Last Updated : March 1, 2018)
Generic Name:
migalastat
Project Status:
Complete
Therapeutic Area:
Fabry Disease
Manufacturer:
Amicus Therapeutics
Call for patient/clinician input open:
Brand Name:
Galafold
Project Line:
Reimbursement Review
Project Number:
SR0522-000
Call for patient/clinician input closed:

Details

Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Fabry Disease
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Call for patient input posted3May 05, 2017
Patient group input closed3June 26, 2017
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 21, 2017
Patient group comments on input summary closedJuly 28, 2017
Clarification:

- Patient input summary feedback received

Submission receivedJune 09, 2017
Submission accepted for reviewJune 23, 2017
Review initiatedJuly 05, 2017
Clarification:

- Submission temporarily suspended pending receipt of information

- Additional information has been received and the temporary suspension of the review has been lifted

Draft CDR review report(s) sent to applicantOctober 23, 2017
Comments from applicant on draft CDR review report(s) receivedNovember 01, 2017
Redaction requests from applicant on draft CDR review report(s) receivedNovember 08, 2017
CDR review team's comments on draft CDR review report(s) sent to applicantDecember 01, 2017
Canadian Drug Expert Committee (CDEC) meetingDecember 13, 2017
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJanuary 03, 2018
Embargo4 period ended and validation of redacted CDR review report(s) receivedJanuary 17, 2018
CDEC Final Recommendation issued to applicant and drug plansJanuary 24, 2018
CDEC Final Recommendation posted5January 26, 2018
Final CDR review report(s) and patient input posted5February 05, 2018

Files

Recommendation and Reasons

Clinical Report

Pharmacoeconomic Report

Patient Group Input Submissions